0
Abstract: Poster Presentations |

A BEFORE AND AFTER COMPARISON OF SYSTEMIC CORTICOSTEROID DOSING FOR THE INPATIENT TREATMENT OF STATUS ASTHMATICUS FREE TO VIEW

Courtney Edwards, PharmD*; Kendra Bosley, PharmD; Stephanie Simms, PharmD; Brian Yarberry, PharmD; Nemr S. Eid, MD
Author and Funding Information

Kosair Children's Hospital, Louisville, KY


Chest


Chest. 2009;136(4_MeetingAbstracts):32S-c-33S. doi:10.1378/chest.136.4_MeetingAbstracts.32S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  In 2007, the NHLBI updated asthma guidelines suggesting a much lower dose of systemic corticosteroids for status asthmaticus. Accordingly, we revised our order set at Kosair Children's Hospital to reflect these changes by reducing the daily dose from 240 mg/day to 60 mg/day. The purpose of this study was to determine if decreasing the total daily dose of systemic corticosteroids affected the length of hospital stay.

METHODS:  A before-and-after chart review of patients hospitalized at Kosair Children's Hospital for status asthmaticus. Eligible patients had received methylprednisolone, prednisolone, or prednisone. Steroid dosing for Group 1 was 1 mg/kg/dose every 6 hours (max 240 mg/day) and 0.5–1 mg/kg/dose every 12 hours (max 60 mg/day) for Group 2. Inclusion criteria: patients < 18 years of age admitted with a diagnosis of status asthmaticus to a regular nursing unit who were prescribed steroids following one of the above protocols. Patients who were admitted to the intensive care unit were excluded. The primary outcome measure was the average length of stay between the two groups.

RESULTS:  A total of 292 patients were identified, 152 patients in Group 1 and 141 patients in Group 2. The average length of stay for Group 1 = 2.01 days and Group 2 = 1.98 days (p = 0.8417) and average initial step of asthma therapy for both groups was Step 2. There was no effect on length of stay (p = 0.0833). In Group 1, 11 patients received intravenous magnesium sulfate compared with 10 patients in Group 2. No difference was found between the groups regarding length of stay (p = 0.7).

CONCLUSION:  There was no statistically significant difference between groups with respect to length of stay due to the decrease in daily systemic corticosteroid dose. Therefore, we conclude that decreasing the daily dose of systemic corticosteroids for status asthmaticus does not affect the length of stay.

CLINICAL IMPLICATIONS:  We conclude that lower dose ICS may be helpful in most children admitted with status asthmaticus. Further prospective studies are needed to confirm our findings.

DISCLOSURE:  Courtney Edwards, Consultant fee, speaker bureau, advisory committee, etc. AstraZeneca, Schering-Plough, Teva; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Guidelines
Rheumatoid arthritis. The management of rheumatoid arthritis in adults.
National Clinical Guideline Centre for Acute and Chronic Conditions | 9/18/2009
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543